Shark Tank’s Kevin O’Leary, Wesana (WSNAF) CEO Daniel Carcillo and director at Mass General Hospital’s Center for the Neuroscience of Psychedelics Dr. Sharmin Ghaznavi.
Recent Wall Street...
Valhalla Ventures backs visionary founders at the forefront of social and technological movements that younger generations care about most.
The Psychedelic Renaissance is roaring. Over the past...
Institutional Analyst Inc. announced the release of the 2021 Psychedelic Investor Guide on Monday, October 18th. The Psychedelic Investor Guide is the most comprehensive and easy to use guide covering...
To appear on an upcoming episode on Psychedelic Investor TV in conjunction with New to the Street TV airing on News Max, contact Roland Rick Perry at 310-594-8062 or Roland@InstitutionalAnalyst.com...
News Channel 5 Nashville. Ketamine infusions are being used to treat patients with severe depression. The medicine is also a treatment for curb substance abuse addictions.
Pasithea Therapeutics recently raised $24 million at its initial public offering (“IPO”). The Company’s Common Stock began trading on The Nasdaq Capital Market on September 15, 2021, under the...
"I believe that we are on the verge of curing, as opposed to simply treating, certain psychiatric maladies." Dr. Jeffrey Kamlet, Chief Medical Officer of Ehave.
